Status:
COMPLETED
Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Autoimmune Liver Disease
Eligibility:
All Genders
18-75 years
Brief Summary
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department...
Detailed Description
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department...
Eligibility Criteria
Inclusion
- 1\) Patients with autoimmune liver disease: All enrolled autoimmune liver diseases meet the diagnostic criteria of China's Consensus on Diagnosis and Treatment of Autoimmune Liver Disease (2015);
- 2\) no hormones and / or immunosuppressants and other liver protection drugs;
- 3\) Sign the written informed consent form.
Exclusion
- 1\) Combine other hepatitis virus (HCV, HDV) infections;
- 2\) viral liver disease;
- 3\) HIV infection;
- 4\) long-term alcohol abuse and / or other liver damage drugs;
- 5\) mental illness;
- 6\) Evidence of liver tumors (liver cancer or AFP \> 100 ng/ml);
- 7\) decompensated cirrhosis;
- 8\) Serious diseases such as heart, brain, lung, kidney, etc. can not participate in long-term follow-up;
- 9\) There are hormones and / or immunosuppressants and other liver protection drugs.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04028869
Start Date
March 1 2018
End Date
March 30 2019
Last Update
July 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
liver disease center, Beijing Ditan Hospital
Beijing, Beijing Municipality, China, 100015